Treating hepatitis C in lower-income countries

N Engl J Med. 2014 May 15;370(20):1869-71. doi: 10.1056/NEJMp1400160. Epub 2014 Apr 10.

Authors

Channa R Jayasekera¹, Michele Barry, Lewis R Roberts, Mindie H Nguyen

Affiliation

¹ From the Division of Gastroenterology and Hepatology (C.R.J., M.H.N.) and the Department of Medicine (C.R.J., M.B., M.H.N.), Stanford University Medical Center; and the Center for Innovation in Global Health, Stanford University (M.B.) - both in Stanford, CA; and the Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN (L.R.R.).

PMID: 24720680
DOI: 10.1056/NEJMp1400160

No abstract available

MeSH terms

Antiviral Agents / economics
Antiviral Agents / therapeutic use*
Developing Countries
Hepacivirus
Hepatitis C / drug therapy*
Humans
Protease Inhibitors / therapeutic use
RNA-Dependent RNA Polymerase / antagonists & inhibitors

Substances

Antiviral Agents
Protease Inhibitors
RNA-Dependent RNA Polymerase